Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Trial Evaluating the Impact of an in Situ Immunization Strategy With Intra-Tumoral Injections of Pexa-Vec in Combination With Ipilimumab in Metastatic / Advanced Solid Tumors With Injectable Lesions

Next Previous
Search
Trial Profile

A Phase I Dose Escalation Trial Evaluating the Impact of an in Situ Immunization Strategy With Intra-Tumoral Injections of Pexa-Vec in Combination With Ipilimumab in Metastatic / Advanced Solid Tumors With Injectable Lesions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Solid tumours
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ISI-JX

    • Most Recent Events

    • 22 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 23 Mar 2022 Planned End Date changed from 1 Mar 2022 to 1 Sep 2022.
    • 23 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top